In This Article:
Over the last 7 days, the United States market has risen 5.2%, contributing to a 9.9% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment of growth, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| MINISO Group Holding (NYSE:MNSO) | $17.60 | $34.83 | 49.5% |
| Lantheus Holdings (NasdaqGM:LNTH) | $103.96 | $203.99 | 49% |
| Trade Desk (NasdaqGM:TTD) | $54.67 | $106.35 | 48.6% |
| SharkNinja (NYSE:SN) | $81.41 | $160.42 | 49.3% |
| Curbline Properties (NYSE:CURB) | $22.89 | $45.04 | 49.2% |
| CBIZ (NYSE:CBZ) | $67.22 | $133.31 | 49.6% |
| Ligand Pharmaceuticals (NasdaqGM:LGND) | $111.38 | $220.47 | 49.5% |
| StoneCo (NasdaqGS:STNE) | $14.08 | $27.73 | 49.2% |
| BigCommerce Holdings (NasdaqGM:BIGC) | $5.29 | $10.31 | 48.7% |
| Roku (NasdaqGS:ROKU) | $69.28 | $135.72 | 49% |
Let's explore several standout options from the results in the screener.
GeneDx Holdings
Overview: GeneDx Holdings Corp. is a genomics company that offers genetic testing services and has a market cap of approximately $3.21 billion.
Operations: The company generates revenue through its Gene Dx segment, contributing $302.29 million, and its Legacy Sema4 segment, which adds $3.16 million.
Estimated Discount To Fair Value: 14.8%
GeneDx Holdings is trading at US$116.97, 14.8% below its estimated fair value of US$137.35, indicating potential undervaluation based on cash flows. The company reported a revenue increase to US$305.45 million in 2024, with expected growth driven by strategic expansions into areas like Inborn Errors of Immunity and cerebral palsy testing. Despite recent share price volatility, GeneDx's focus on genetic insights and patient care could enhance future profitability and revenue growth prospects in the healthcare sector.
-
The growth report we've compiled suggests that GeneDx Holdings' future prospects could be on the up.
-
Click here to discover the nuances of GeneDx Holdings with our detailed financial health report.
Dayforce
Overview: Dayforce Inc. is a human capital management software company operating in the United States, Canada, Australia, and internationally, with a market cap of approximately $9.06 billion.
Operations: The company generates revenue of $1.76 billion from its Human Capital Management (HCM) segment.
Estimated Discount To Fair Value: 31.4%
Dayforce, trading at US$57.35, is 31.4% below its estimated fair value of US$83.57, suggesting it may be undervalued based on cash flows. Despite a decline in profit margins from 3.6% to 1%, revenue grew to US$1.76 billion in 2024 and is forecasted to outpace the broader U.S. market growth rate with a projected annual earnings increase of 36.3%. Recent partnerships and strategic financial adjustments could support future valuation improvements.